Abstract Obesity has emerged as a major global health challenge and the rising epidemic of obesity is closely associated with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction- and alcohol-associated liver disease (MetALD). Overall, an increased prevalence of obesity is reported in patients with advanced chronic liver disease (ACLD) and impacts the prognosis of the disease, as an increase in body mass index (BMI) is recognized as a modifiable risk factor for progression of liver disease regardless of the etiology. The recent approval of novel efficient and well-tolerated anti-obesity medications offers novel perspectives along with therapeutic lifestyle changes and bariatric surgery in the personalized management of patients living with obesity and associated liver disease.
Caussy et al. (Thu,) studied this question.